Evidence map›Paper›PMID 26389583›Full record

ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2016

Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate.

Daire O'Shea, John Law, Adrian Egli, Donna Douglas, Gary Lund, Sarah Forester, Joshua Lambert, Mansun Law, Dennis R Burton, D L J Tyrrell and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daire O'SheaTransplant Infectious Diseases, Alberta Transplant Institute, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
John LawLi Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
Adrian EgliLi Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
Donna DouglasLi Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
Gary LundKMT Hepatech, University of Alberta, Edmonton, Alberta, Canada.
Sarah ForesterDepartment of Food Science, Pennsylvania State University, State College, PA.
Joshua LambertDepartment of Food Science, Pennsylvania State University, State College, PA.
Mansun LawDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA.
Dennis R BurtonDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA.
D L J TyrrellLi Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
Michael HoughtonLi Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
Atul HumarToronto General Hospital, University Health Network, Multi-Organ Transplant Program, Toronto, Ontario, Canada.
Norman KnetemanLi Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.

Funding

Understanding human neutralizing antibodies to hepatitis C virusR01AI079031 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2008 to 2017
$4.6M
Probing the antibody response to HCV to facilitate rational immunogen designR01AI071084 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2009 to 2013
$3.1M
Canadian Institutes of Health ResearchNIAID NIH HHS R01 AI071084NIAID NIH HHS R01AI071084NIAID NIH HHS R01 AI079031NIAID NIH HHS R01AI079031
6 · The paper itself

Abstract

The anti-hepatitis C virus (HCV) activity of a novel monoclonal antibody (mAb; AR4A) and epigallocatechin gallate (EGCG) were studied in vitro using a HCV cell culture system and in vivo using a humanized liver mouse model capable of supporting HCV replication. Alone, both exhibit reliable cross-genotype HCV inhibition in vitro, and combination therapy completely prevented HCV infection. In vitro AR4A mAb (alone and combined with EGCG) robustly protects against the establishment of HCV genotype 1a infection. EGCG alone fails to reliably protect against an HCV challenge. In conclusion, AR4A mAb represents a safe and efficacious broadly neutralizing antibody against HCV applicable to strategies to safely prevent HCV reinfection following liver transplantation, and it lends further support to the concept of HCV vaccine development. The poor bioavailability of EGCG limits HCV antiviral activity in vitro.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsBroadly Neutralizing AntibodiesCatechinCell LineDisease Models, AnimalDose-Response Relationship, DrugDrug Therapy, CombinationGenotypeHepatitis CHepatitis VirusesHumansLiverMice, SCIDAntibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsAR4A cross-neutralizing monoclonal antibodyBroadly Neutralizing AntibodiesCatechinepigallocatechin gallate

Identifiers

PMID26389583
PMCPMC4769112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.